SOLICITATION NOTICE
Q -- Measure AMH, FSH and Inhibin from the JANUS biobank
- Notice Date
- 8/2/2012
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120159-MD
- Archive Date
- 8/31/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis with the University of Southern California of 3720 S. Flower St Los Angeles, CA 90089 to measure AMH, FSH and Inhibin in 440 samples from the JANUS biobank. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire Green Products or Services under this contract. The period of performance shall be twelve (12) months from date of award. Ovarian cancer is the most fatal gynecologic malignancy. Several reproductive factors are associated with ovarian cancer risk, including parity, age at menarche, age at menopause and lifetime ovulatory cycles. Anti-Muellerian Hormone (AMH) is a protein hormone from the TGF-beta family that is expressed in granulosa cells of growing non-selected follicles. AMH, together with FSH and Inhibin, serves as a marker of ovarian function and is routinely evaluated to evaluate infertility. AMH levels increase with puberty and decrease until menopause when AMH levels become undetectable. The relationship of AMH with reproductive risk factors for ovarian cancer and experimental data indicating that AMH can suppress ovarian cancer growth suggest that increased AMH levels may be associated with decreased risk of ovarian cancer. The purpose is to have high quality serum measurements for AMH, FSH and Inhibin. The University of Southern California (USC) has extensive experience with these assays and has conducted important developmental and technical work that established these markers and helped understand their role in various cancerous and non-cancerous conditions. USC measured these hormones in a previous study of breast cancer risk that motivated the current effort. USC is also the laboratory resource for an ongoing complementary effort of measuring AMH levels and ovarian cancer risk in various cohort studies. It will be important to compare these findings to the parallel ovarian effort and the previous effort. The ability to pool results with the other ovarian cancer effort is crucial for the primary research questions, since ovarian cancer is very heterogeneous and requires evaluating a large sample size for definitive answers. With a combined analysis of the data, NCI will be able to get a definitive result on the role of AMH, FSH, and Inhibin in ovarian carcinogenesis. Due to the need for compatibility to parallel and previous studies, the University of Southern California is the only known source capable of fulfilling the requirements of this procurement. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 16, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120159-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120159-MD/listing.html)
- Record
- SN02824224-W 20120804/120802235719-fc4db98e9993b628d8a1f2aa85a0c6c7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |